Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Leukemia, Myeloid, Chronic-Phase 6Leukemia, Myeloid 2Leukemia 2Bronchiolitis Obliterans Syndrome 2Malignant Solid Tumors 1Hematologic Diseases 1

Interventions

fludarabine 7Tacrolimus 6Cyclophosphamide 6Whole-Body Irradiation 5Mycophenolic Acid 5Busulfan 5fludarabine phosphate 4Peripheral Blood Stem Cell Transplantation 4Imatinib Mesylate 4Cytarabine 4Sirolimus 3Melphalan 3thymoglobulin 2asciminib 2Thiotepa 2Patient Reported Outcome Measures 2Mesna 2Bone Marrow Transplantation 2Antilymphocyte Serum 2venetoclax 1ponatinib 1pegfilgrastim 1nilotinib 1nicotinamide-beta-riboside 1methanesulfonic acid 1lonafarnib 1lestaurtinib 1glasdegib 1flumatinib 1aldesleukin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Myeloid × asciminib × Clear all
NCT05143840 2026-06-02

ALERTCML

University of Alabama at Birmingham

Phase 2 Recruiting
100 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT03578367 2026-04-21

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

Novartis

Phase 2 Completed
104 enrolled 33 charts
MyeloidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡